HealthEquity (HQY) 10-Q11 Dec 142015 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Oct. 31, 2014	Nov. 30, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'HEALTHEQUITY INC	'
Entity Central Index Key	'0001428336	'
Current Fiscal Year End Date	'--01-31	'
Entity Filer Category	'Non-accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	31-Oct-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	54,753,740
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Oct. 31, 2014	Jan. 31, 2014
In Thousands, unless otherwise specified	Oct. 31, 2014	Jan. 31, 2014
Current assets	'	'
Cash and cash equivalents	$107,854	$13,917
Accounts receivable, net of allowance for doubtful accounts of $40 as of October 31, 2014 and January 31, 2014	6,054	5,705
Inventories	756	391
Deferred tax asset	1,392	3,080
Prepaid expenses	2,787	663
Total current assets	118,843	23,756
Property and equipment, net	2,688	1,992
Intangible assets, net	26,250	24,691
Goodwill	4,651	4,651
Other investments	305	0
Total assets	152,737	55,090
Current liabilities	'	'
Accounts payable	908	2,368
Accrued compensation	3,009	4,134
Accrued liabilities	2,419	2,927
Total liabilities	6,336	9,429
Long-term liabilities	'	'
Deferred rent	481	393
Series D-3 redeemable convertible preferred stock derivative liability	0	6,182
Deferred tax liability	5,416	5,078
Total long-term liabilities	5,897	11,653
Total liabilities	12,233	21,082
Commitments and contingencies (see note 5)	'	'
Redeemable convertible preferred stock, $0.0001 par value, 26,473 shares authorized; no shares issued and outstanding as of October 31, 2014 and 17,349 shares issued and outstanding as of January 31, 2014; liquidation preference of $0 and $43,128 as of October 31, 2014 and January 31, 2014, respectively	0	46,714
Total stockholdersâ€™ equity (deficit)	'	'
Common stock, $0.0001 par value, 900,000 shares authorized, 54,754 and 7,038 shares issued and outstanding as of October 31, 2014 and January 31, 2014, respectively	5	1
Common stock warrants	0	2,334
Additional paid-in capital	154,874	0
Accumulated deficit	-14,375	-23,170
Total stockholdersâ€™ equity (deficit)	140,504	-12,706
Total liabilities, redeemable convertible preferred stock and stockholdersâ€™ equity (deficit)	152,737	55,090
Redeemable convertible preferred stock	'	'
Long-term liabilities	'	'
Redeemable convertible preferred stock, $0.0001 par value, 26,473 shares authorized; no shares issued and outstanding as of October 31, 2014 and 17,349 shares issued and outstanding as of January 31, 2014; liquidation preference of $0 and $43,128 as of October 31, 2014 and January 31, 2014, respectively	0	46,714
Convertible preferred stock	'	'
Total stockholdersâ€™ equity (deficit)	'	'
Convertible preferred stock, $0.0001 par value, 6,738 shares authorized, no shares issued and outstanding as of October 31, 2014 and 6,156 shares issued and outstanding as of January 31, 2014; liquidation preference of $0 and $12,764 as of October 31, 2014 and January 31, 2014, respectively	$0	$8,129

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Phantom) (USD $)	Oct. 31, 2014	Jan. 31, 2014
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2014	Jan. 31, 2014
Allowance for doubtful accounts	$40	$40
Redeemable Convertible Preferred Stock, Shares Outstanding	0	17,349,000
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	900,000,000	900,000,000
Common Stock, Shares, Issued	54,754,000	54,754,000
Common Stock, Shares, Outstanding	7,038,000	7,038,000
Redeemable convertible preferred stock	'	'
Redeemable Convertible Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Redeemable Convertible Preferred Stock, Shares Authorized	26,473,000	26,473,000
Redeemable Convertible Preferred Stock, Shares Issued	17,349,000	17,349,000
Redeemable Convertible Preferred Stock, Shares Outstanding	17,349,000	17,349,000
Redeemable Convertible Preferred Stock, Liquidation Preference	0	43,128
Convertible preferred stock	'	'
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00
Preferred Stock, Shares Authorized	6,738,000	6,738,000
Preferred Stock, Shares Issued	6,156,000	6,156,000
Preferred Stock, Shares Outstanding	6,156,000	6,156,000
Liquidation preference	$0	$12,764

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Operations And Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Revenue	'	'	'	'
Account fee revenue	$11,086	$7,496	$32,022	$21,721
Custodial fee revenue	6,196	4,816	17,557	13,913
Card fee revenue	4,317	2,853	12,848	8,929
Other revenue	263	83	557	291
Total revenue	21,862	15,248	62,984	44,854
Cost of services	'	'	'	'
Account costs	7,057	4,977	20,188	14,677
Custodial costs	1,050	858	2,994	2,737
Card costs	1,467	1,006	4,284	2,989
Other costs	56	29	58	71
Total cost of services	9,630	6,870	27,524	20,474
Gross profit	12,232	8,378	35,460	24,380
Operating expenses	'	'	'	'
Sales and marketing	2,275	1,876	6,829	5,458
Technology and development	2,811	1,803	7,299	5,131
General and administrative	2,443	894	5,252	2,629
Amortization of acquired intangible assets	409	409	1,227	1,227
Total operating expenses	7,938	4,982	20,607	14,445
Income from operations	4,294	3,396	14,853	9,935
Other expense	'	'	'	'
Loss on revaluation of redeemable convertible preferred stock derivative	0	-109	-735	-109
Other expense, net	-145	-29	-276	-152
Total other expense	-145	-138	-1,011	-261
Income before income taxes	4,149	3,258	13,842	9,674
Income tax provision	1,100	1,280	5,047	3,724
Net income and comprehensive income	3,049	1,978	8,795	5,950
Comprehensive income	3,049	1,978	8,795	5,950
Net income attributable to common stockholders:	'	'	'	'
Basic (in dollars)	3,020	607	10,245	1,717
Diluted (in dollars)	$3,036	$1,213	$9,530	$3,520
Net income per share attributable to common stockholders:	'	'	'	'
Basic (in dollars per share)	$0.06	$0.11	$0.44	$0.31
Diluted (in dollars per share)	$0.05	$0.04	$0.19	$0.12
Weighted-average number of shares used in computing net income per share attributable to common stockholders	'	'	'	'
Basic (in shares)	53,678	5,582	23,232	5,548
Diluted (in shares)	57,553	28,725	50,052	28,705

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (USD $)	Total	Convertible preferred stock	Common stock	Common stock warrants	Additional paid-in capital	Accumulated deficit
In Thousands, except Share data, unless otherwise specified	Total	Convertible preferred stock	Common stock	Common stock warrants	Additional paid-in capital	Accumulated deficit
Opening balance at Jan. 31, 2014	($12,706)	$8,129	$1	$2,334	$0	($23,170)
Opening balance at Jan. 31, 2014	46,714	'	'	'	'	'
Opening balance, shares at Jan. 31, 2014	17,349,000	'	'	'	'	'
Opening balance, shares at Jan. 31, 2014	'	6,156,000	7,038,000	'	'	'
Redeemable convertible preferred stock	'	'	'	'	'	'
Conversion of preferred stock to common stock upon initial public offering, shares	-17,349	'	'	'	'	'
Conversion of preferred stock to common stock upon initial public offering	-42,693	'	'	'	'	'
Redeemable convertible preferred stock accretion	-4,021	'	'	'	'	'
Stockholdersâ€™ equity (deficit)	'	'	'	'	'	'
Issuance of series D-3 redeemable convertible preferred stock cash dividend	-347	'	'	'	-347	'
Issuance of common stock cash dividend	-50,000	'	'	'	-50,000	'
Exercise of 2,972 warrants at $0.8008 per share, shares	'	'	2,972,000	'	'	'
Exercise of 2,972 warrants at $0.8008 per share	2,380	'	'	-2,334	4,714	'
Exercise of 1,793 options at $1.3370 per share	1,793,000	'	1,793,000	'	'	'
Exercise of 1,793 options at $1.3370 per share	2,397	'	'	'	2,397	'
Conversion of preferred stock to common stock upon initial public offering, shares	'	-6,156,000	32,486,000	'	'	'
Conversion of preferred stock to common stock upon initial public offering	42,693	-8,129	3	'	50,819	'
Issuance of common stock, shares	'	'	10,465,000	'	'	'
Issuance of common stock	132,587	'	1	'	132,586	'
Stock-based compensation	793	'	'	'	793	'
Tax benefit on stock options exercised	2,974	'	'	'	2,974	'
Redeemable convertible preferred stock accretion	4,021	'	'	'	4,021	'
Reclassification of series D-3 redeemable convertible preferred stock derivative liability	6,917	'	'	'	6,917	'
Net income	8,795	'	'	'	'	8,795
Ending balance at Oct. 31, 2014	140,504	0	5	0	154,874	-14,375
Ending balance at Oct. 31, 2014	$0	'	'	'	'	'
Ending balance, shares at Oct. 31, 2014	0	'	'	'	'	'
Ending balance, shares at Oct. 31, 2014	'	0	54,754,000	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (USD $)	9 Months Ended
	Oct. 31, 2014
Statement of Stockholders' Equity [Abstract]	'
Exercise price of warrants	$0.80
Exercise price	$1.34

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements Of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013
Cash flows from operating activities:	'	'
Net income	$8,795	$5,950
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	4,187	3,140
Loss on revaluation of redeemable convertible preferred stock derivative	735	109
Imputed interest on notes payable	0	30
Deferred taxes	2,026	3,670
Stock-based compensation	793	44
Changes in operating assets and liabilities:	'	'
Restricted cash	0	791
Accounts receivable	-349	-186
Inventories	-365	-204
Prepaid expenses	-2,124	-230
Accounts payable	-1,542	-533
Due to trust	0	-791
Accrued compensation	-1,125	-555
Accrued liabilities	-540	1,080
Income taxes payable	0	-77
Deferred rent	88	199
Net cash provided by operating activities	10,579	12,437
Cash flows from investing activities:	'	'
Purchase of property and equipment	-1,477	-1,226
Purchase of software and capitalized software development costs	-4,851	-2,735
Purchase of other investments	-305	0
Net cash used in investing activities	-6,633	-3,961
Cash flows from financing activities:	'	'
Repayment of notes payable	0	-1,500
Dividend payments	-50,347	0
Proceeds from initial public offering, net of payments for offering costs	132,587	0
Proceeds from exercise of common stock options	2,397	232
Proceeds from exercise of common stock warrants	2,380	17
Tax benefit from exercise of common stock options	2,974	0
Net cash provided by (used in) financing activities	89,991	-1,251
Increase in cash and cash equivalents	93,937	7,225
Beginning cash and cash equivalents	13,917	5,905
Ending cash and cash equivalents	107,854	13,130
Supplemental disclosures of non-cash investing and financing activities:	'	'
Conversion of preferred stock to common stock	50,822	0
Preferred stock accretion	4,021	925
Reclassification of series D-3 redeemable convertible preferred stock derivative liability	6,917	0
Common stock warrants exercised	2,334	35
Series D-3 redeemable convertible preferred stock dividend	$0	$519

Summary_of_business_and_signif

Summary of business and significant accounting policies	9 Months Ended
Summary of business and significant accounting policies	Oct. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Summary of business and significant accounting policies	'
	Summary of business and significant accounting policies
	HealthEquity, Inc. was incorporated in the state of Delaware on September 18, 2002, and was organized to offer a full range of innovative solutions for managing health care accounts (Health Savings Accounts, Health Reimbursement Arrangements, and Flexible Spending Accounts) for health plans, insurance companies, and third-party administrators.
	Principles of consolidation—The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, First HSA, LLC, First Horizon MSaver, Inc., HEQ Insurance Services, Inc., and HealthEquity Advisors, LLC (collectively referred to as the "Company"). All significant intercompany balances and transactions have been eliminated.
	Basis of presentation—The accompanying condensed consolidated financial statements as of October 31, 2014 and for the three and nine months ended October 31, 2014 and 2013 are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. In the opinion of management, the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Certain information and note disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company's final prospectus (dated July 30, 2014) filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933 on August 1, 2014.
	The fiscal year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP.
	Initial public offering—On August 5, 2014, the Company consummated its initial public offering ("IPO") and issued and sold 10,465,000 shares of its common stock at a public offering price of $14.00 per share, less the underwriters' discount. The Company received net proceeds of approximately $132.6 million after deducting underwriters' discounts and commissions of approximately $10.2 million and other offering expenses payable by the Company of approximately $3.7 million. The underwriting discounts and commissions and other offering expenses were recorded as an offset against the IPO proceeds in additional paid-in capital upon the closing of the IPO on August 5, 2014.
	Capital structure—On July 14, 2014, the Company's board of directors approved an amended and restated certificate of incorporation, pursuant to which the total number of shares of all classes of capital stock that the Company is authorized to issue is 1,000,000,000 shares, including 900,000,000 shares of common stock and 100,000,000 shares of preferred stock, par value $0.0001 per share. The amended and restated certificate of incorporation was filed with the Secretary of State of the State of Delaware and became effective on August 5, 2014.
	On July 14, 2014, the Company's board of directors declared a cash dividend in an aggregate amount of $50.0 million on shares of the Company's common stock outstanding on August 4, 2014 (after giving effect to the conversion of all outstanding convertible preferred stock and redeemable convertible preferred stock into shares of common stock). The terms of each of the Company's stock plans, including the 2003 Director Stock Plan, 2003 Stock Plan, 2005 Stock Plan, 2006 Stock Plan, 2009 Stock Plan and the 2014 Equity Incentive Plan (the "Incentive Plan") requires an adjustment to outstanding stock options to prevent dilution of the holders’ interests as a result of the foregoing special dividend. Accordingly, the Company's board of directors approved an adjustment to reduce the exercise price of each of the stock options outstanding as of the record date, August 4, 2014, for the dividend by $1.00.
	As of the close of business on August 4, 2014, all of the Company's redeemable convertible preferred stock and convertible preferred stock converted into 32,486,588 shares of common stock.
	Recent accounting pronouncements—On May 28, 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in GAAP when it becomes effective. The new standard is effective for our annual and interim reporting periods beginning February 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on the consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor determined the effect of the standard on the ongoing financial reporting.
	Revision of previously issued financial statements—In the three months ended October 31, 2014, the Company identified an error that originated in the three months ended July 31, 2014. This error was caused by using an incorrect fair value amount in calculating the windfall tax benefit for a portion of the vested options exercised during the period. The adjustment increased prepaid expenses and additional paid-in capital by approximately $1.0 million. The error also decreased cash provided by operating activities by $1.0 million and increased cash provided by financing activities by the same amount. The error had no impact to the condensed consolidated statement of operations and comprehensive income. The correction has been properly reflected in both the condensed consolidated balance sheets as of October 31, 2014, and in the condensed consolidated statements of cash flows for the nine months ended October 31, 2014. The Company determined this error did not materially impact the July 31, 2014 financial statements nor the October 31, 2014 financial statements; however, in order to correctly present the financial statements, the July 31, 2014 financial statements will be revised the next time the financial statements are filed to reflect this correction.

Net_income_per_share_attributa

Net income per share attributable to common stockholders	9 Months Ended
	Oct. 31, 2014
Earnings Per Share [Abstract]	'
Net income per share attributable to common stockholders	'
	Net income per share attributable to common stockholders
	The Company computes net income per share of common stock in conformity with the two-class method required for participating securities. The Company considers its series D-3 redeemable convertible preferred stock to be participating securities as the holders of the preferred stock were entitled to receive a dividend in the event that a dividend is paid on common stock. The following table sets forth the computation of basic and diluted net income per share attributable to common stockholders:


	(in thousands, except per share data)	Three months ended October 31,						Nine months ended October 31,

		2014			2013			2014			2013

	Numerator (basic and diluted):

	Net income	$	3,049		$	1,978		$	8,795		$	5,950

	Add back (deduction): accretion of redeemable convertible preferred stock	—			(245		)	4,021			(925		)

	Less: dividend on redeemable convertible preferred stock and dividend on convertible preferred stock	(21		)	(650		)	(1,286		)	(1,951		)

	Less: undistributed income attributed to redeemable convertible preferred stockholders	(8		)	(476		)	(1,285		)	(1,357		)

	Net income attributable to common stockholders for basic earnings per share	$	3,020		$	607		$	10,245		$	1,717

	Add back: dividend of redeemable convertible preferred stock	15			241			1,286			723

	Add back (deduction): accretion on redeemable convertible preferred stock and dividend on convertible preferred stock	—			75			(4,021		)	284

	Add back: series D-3 derivative liability revaluations	—			—			735			—

	Add back: adjustment to undistributed income attributed to redeemable convertible preferred stockholders	1			290			1,285			796

	Net income attributable to common stockholders for diluted earnings per share	$	3,036		$	1,213		$	9,530		$	3,520



	Denominator (basic):

	Weighted-average common shares outstanding	53,678			5,582			23,232			5,548

	Denominator (diluted):

	Weighted-average common shares outstanding	53,678			5,582			23,232			5,548

	Effect of potential dilutive securities:

	Weighted-average dilutive effect of stock options	2,944			1,156			3,290			1,168

	Weighted-average dilutive effect of common shares from stock warrants	3			2,579			1,634			2,581

	Dilutive effect from preferred stock assuming conversion	928			19,408			21,896			19,408

	Weighted-average common shares outstanding	57,553			28,725			50,052			28,705

	Net income per share attributable to common stockholders:

	Basic	$	0.06		$	0.11		$	0.44		$	0.31

	Diluted	$	0.05		$	0.04		$	0.19		$	0.12


	For the three months ended October 31, 2014 and 2013, approximately 322,000 and 14.5 million shares, respectively, attributable to outstanding series D-3 redeemable convertible preferred stock, series C redeemable convertible preferred stock and stock options were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.
	For the nine months ended October 31, 2014 and 2013, approximately 164,000 and 14.4 million shares, respectively, attributable to outstanding series D-3 redeemable convertible preferred stock, series C redeemable convertible preferred stock and stock options were excluded from the calculation of diluted earnings per share as their inclusion would have been anti-dilutive.

Property_and_equipment

Property and equipment	9 Months Ended
	Oct. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property and equipment	'
	Property and equipment
	Property and equipment consisted of the following as of October 31, 2014 and January 31, 2014:


	(in thousands)	31-Oct-14			31-Jan-14

	Leasehold improvements	$	482		$	329

	Furniture and fixtures	1,317			1,094

	Computer equipment	4,176			3,075

	Property and equipment, gross	5,975			4,498

	Accumulated depreciation	(3,287		)	(2,506		)

	Property and equipment, net	$	2,688		$	1,992

	Depreciation expense for the three and nine months ended October 31, 2014 was $290,000 and $776,000, respectively, and $215,000 and $562,000 for the three and nine months ended October 31, 2013, respectively.

Intangible_assets_and_goodwill

Intangible assets and goodwill	9 Months Ended
	Oct. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible assets and goodwill	'
	Intangible assets and goodwill
	During the three and nine months ended October 31, 2014, the Company capitalized software development costs of $1.4 million and $3.8 million, respectively, and $343,000 and $948,000 for the three and nine months ended October 31, 2013, respectively, related to significant enhancements and upgrades to its proprietary system.
	The gross carrying amount and associated accumulated amortization of intangible assets is as follows as of October 31, 2014 and January 31, 2014:


	(in thousands)	31-Oct-14			31-Jan-14

	Amortized intangible assets:

	Capitalized software development costs	$	9,073		$	5,290

	Software	4,532			3,351

	Acquired intangible member assets	24,563			24,563

	Intangible assets, gross	38,168			33,204

	Accumulated amortization	(11,918		)	(8,513		)

	Intangible assets, net	$	26,250		$	24,691

	During the three and nine months ended October 31, 2014, the Company incurred and expensed a total of $1.2 million and $3.2 million, respectively, and $541,000 and $1.7 million for the three and nine months ended October 31, 2013, respectively, in software development costs primarily related to the post-implementation and operation stages of its proprietary software.
	Amortization expense for the three and nine months ended October 31, 2014 was $1.3 million and $3.4 million, respectively, and $936,000 and $2.6 million for the three and nine months ended October 31, 2013, respectively.
	All of the Company’s goodwill was generated from the acquisition of First Horizon MSaver, Inc. on August 11, 2011. There have been no changes to the goodwill carrying value during the three and nine months ended October 31, 2014 and 2013.

Commitment_and_contingencies

Commitment and contingencies	9 Months Ended
Commitment and contingencies	Oct. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and contingencies	'
	Commitments and contingencies
	The Company’s principal commitments and contingencies consist of a processing services agreement with a vendor, and obligations for office space, data storage facilities, equipment and certain maintenance agreements under long-term, non-cancelable operating leases. These commitments as of January 31, 2014 are disclosed in the Company’s consolidated financial statements included in its final prospectus (dated July 30, 2014) filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933 on August 1, 2014, and did not change materially during the three and nine months ended October 31, 2014 except for the following:
	In March 2014, the Company modified its corporate office lease to expand its existing space for an additional commitment of $1.1 million over the term of the original lease.
	Lease expense for office space for the three and nine months ended October 31, 2014 was $374,000 and $944,000, respectively, and $237,000 and $672,000 for the three and nine months ended October 31, 2013, respectively. Expense for other lease agreements for the three and nine months ended October 31, 2014 was $67,000 and $166,000, respectively, and $62,000 and $127,000 for the three and nine months ended October 31, 2013, respectively.

Income_taxes

Income taxes	9 Months Ended
Income taxes	Oct. 31, 2014
Income Tax Disclosure [Abstract]	'
Income taxes	'
	Income taxes

	The Company follows FASB Accounting Standards Codification 740-270, Income Taxes - Interim Reporting, for the computation and presentation of its interim period tax provision. Accordingly, management estimated the effective annual tax rate and applied this rate to the year-to-date pre-tax book income to determine the interim provision for income taxes. For the three and nine months ended October 31, 2014, the Company recorded a provision for income taxes of $1.1 million and $5.0 million, respectively. The resulting effective tax rate was 26.5% and 36.5%, compared with an effective tax rate of 39.3% and 38.5% for the three and nine months ended October 31, 2013, respectively. For the three and nine months ended October 31, 2014, the net impact of discrete tax items caused a 12.1% and 3.1% decrease to the effective tax rate primarily due to the recognition of research and development tax credits, book stock compensation expense on stock options vesting upon the Company's initial public offering treated as a discrete event, and the impact of changes in estimated annual tax rates. For the three and nine months ended October 31, 2013, the net impact of discrete tax items was not significant. The effective tax rate decreased over the same period last year primarily due to discrete tax items, offset by an increase in permanent tax items in relation to income before income taxes, including expiration of the federal research and development tax credits as of December 31, 2013.
	As of October 31, 2014 and January 31, 2014, the Company’s total gross unrecognized tax benefit was $229,000 and $256,000, respectively. As a result of Accounting Standards Update No. 2013-11, certain unrecognized tax benefits have been netted against their related deferred tax assets. As a result, the unrecognized tax benefit recorded as of October 31, 2014 and January 31, 2014 was $53,000 and $47,000, respectively. Substantially all of the gross unrecognized tax benefit, if recognized, would affect the Company’s effective tax rate. The Company anticipates a decrease of $6,000 in total gross unrecognized tax benefits within 12 months of the reporting date related to an uncertain tax position on research and development credits claimed for which a lapse of the applicable statute of limitations is expected.
	The Company files income tax returns with U.S. federal and state taxing jurisdictions and is not currently under examination with any jurisdiction. The Company remains subject to examination by federal and various state taxing jurisdictions for tax years after 2003.

Redeemable_convertible_preferr

Redeemable convertible preferred stock and convertible preferred stock	9 Months Ended
	Oct. 31, 2014
Equity [Abstract]	'
Redeemable convertible preferred stock and convertible preferred stock	'
	Redeemable convertible preferred stock and convertible preferred stock
	In connection with the Company's IPO, all outstanding shares of the Company's convertible preferred stock and redeemable convertible preferred stock converted into 32,486,588 shares of common stock. In accordance with their respective terms, shares of the series A and series B convertible preferred stock and D-3 redeemable convertible preferred stock converted into shares of common stock on a 1:1 basis, shares of series C redeemable and convertible preferred stock converted into shares of common stock on a 1:1.38 basis, shares of the series D-1 redeemable convertible preferred stock converted into shares of common stock on a 1:2 basis, and shares of the series D-2 redeemable convertible preferred stock converted into shares of common stock on a 1:2.27 basis. As a result, as of August 4, 2014, amounts associated with the convertible preferred stock and redeemable convertible preferred stock were reclassified to additional paid-in capital, and no amounts were outstanding as of October 31, 2014.
	As of January 31, 2014, the Company had outstanding shares of series A and B convertible preferred stock and series C, D-1, D-2, and D-3 redeemable convertible preferred stock. Redeemable convertible preferred stock and convertible preferred stock as of January 31, 2014 consisted of the following:


		Shares
	Series	Authorized	Issued and	Liquidation		Carrying
			outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	22,533	$	22,232

	Series D-1	9,000	5,835	8,464		8,340

	Series D-2	3,200	440	719		709

	Series D-3	7,500	4,323	11,412		15,433

	Total redeemable convertible preferred stock	26,473	17,349	$	43,128	$	46,714

	Convertible preferred stock:
	Series A	2,000	2,000	$	3,291	$	2,000

	Series B	4,738	4,156	9,473		6,129

	Total convertible preferred stock	6,738	6,156	$	12,764	$	8,129

Common_stock_warrants

Common stock warrants	9 Months Ended
Common stock warrants	Oct. 31, 2014
Stockholders' Equity Note [Abstract]	'
Common stock warrant	'
	Common stock warrants
	In conjunction with a rights equalization agreement, the Company issued warrants to series A convertible preferred stockholders to purchase 150,000 shares of its common stock for $1.00 per share, The warrants were exercisable through November 2015, of which 26,000 were exercised with 124,000 outstanding as of January 31, 2014. The 124,000 warrants outstanding as January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a fair market value of $51,000 at the date of issuance.
	In conjunction with the issuance of the series B convertible preferred stock, warrants to purchase 400,000 shares of common stock with an exercise price of $1.00 per share were granted to series B convertible preferred stockholders. The warrants were exercisable through February 2014, of which 50,000 were exercised with 350,000 outstanding as of January 31, 2014. Of the 350,000 warrants outstanding as of January 31, 2014, 340,000 were exercised, and 10,000 were forfeited during the nine months ended October 31, 2014. The warrants had a fair market value of $44,000 at the date of issuance.
	The Company issued warrants to purchase an additional 200,000 shares of common stock to series B convertible preferred stockholders with an exercise price of $1.00 per share. The warrants were exercisable through September 2015, of which 5,000 were exercised with 195,000 outstanding as of January 31, 2014. The 195,000 warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a fair market value of $66,000 at the date of issuance.
	In conjunction with the issuance of the series C redeemable convertible preferred stock, the Company issued detachable warrants to purchase 600,000 shares of common stock with an exercise price of $1.50 per share to series C redeemable convertible preferred stockholders. The warrants were exercisable through August 2016, of which 10,000 were exercised with 590,000 outstanding as of January 31, 2014. The 590,000 warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a fair market value of $339,000 at the date of issuance. The Company issued warrants to purchase an additional 1.0 million shares of common stock to series C redeemable convertible preferred stockholders with an exercise price of $0.01 per share. The warrants were exercisable through May 2017, of which 4,000 were exercised with 1.0 million outstanding as of January 31, 2014. The 1.0 million warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a fair market value of $1.6 million at the date of issuance.
	In conjunction with the issuance of the series D-1 redeemable convertible preferred stock, the Company issued detachable warrants to purchase 400,000 shares of common stock with an exercise price of $2.00 per share. The warrants were exercisable upon the option of the stockholder through August 2018, of which 400,000 were outstanding as of January 31, 2014. The 400,000 warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014.
	In conjunction with the issuance of the series D-3 redeemable convertible preferred stock, warrants to purchase 966,000 shares of common stock with an exercise price of $0.01 per share were granted to series D-3 redeemable convertible preferred stockholders. The warrants were exercisable through August 2021, of which 767,000 were exercised with 199,000 outstanding as of January 31, 2014. The warrants outstanding as of January 31, 2014 were all exercised during the nine months ended October 31, 2014. The warrants had a value of $1.7 million at the date of issuance.
	As a result of the foregoing, as of October 31, 2014, there were no warrants outstanding.

Stock_options

Stock options	9 Months Ended
	Oct. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock options	'
	Stock options
	On January 30, 2014, the Company’s board of directors approved, and the Company adopted, the Incentive Plan providing for the issuance of stock options to the directors and employees of the Company to purchase up to an aggregate of 600,000 shares of common stock. No stock options were issued to directors of the Company from the Incentive Plan as of January 31, 2014.
	In July 2014, the Company's board of directors voted to increase the shares of common stock reserved under the Incentive Plan by 2,000,000 shares from 600,000 shares of common stock to 2,600,000 shares of common stock. In addition, the board of directors voted to provide that the number of shares of common stock reserved for issuance under the Incentive Plan will automatically increase on February 1 of each year, beginning as of February 1, 2015 and continuing through and including February 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on January 31 of the preceding fiscal year, or a lesser number of shares determined by the board of directors. As of October 31, 2014, 631,000 shares were available for grant under the Incentive Plan.
	Under the terms of the Incentive Plan, the Company has the ability to grant incentive and nonstatutory stock options. Incentive stock options may be granted only to Company employees. Nonstatutory stock options may be granted to Company employees, directors and consultants. Such options are to be exercisable at prices, as determined by the board of directors, which must be equal to no less than the fair value of the Company's common stock at the date of the grant. Stock options granted under the Incentive Plan generally expire 10 years from the date of issuance, or are forfeited 90 days after termination of employment. Any stock options that are forfeited or that expire are returned to the Incentive Plan.
	During the three and nine months ended October 31, 2014, the Company granted 56,000 and 487,500 time-based stock options to certain directors and key employees, respectively, of which 56,000 and 405,000 vest over a period of 4 years and 82,500 of which vest on January 31, 2015. In addition, during the three and nine months ended October 31, 2014, the Company granted 58,000 and 1.4 million performance-based stock options, respectively, to certain key employees under the Incentive Plan, which vest upon the achievement of certain performance criteria. The performance-based stock options vest upon the attainment of the following performance criteria: (a) 10% of the stock options vest upon attainment of at least $34.5 million in Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") for the fiscal year 2016, (b) 20% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 30% for the fiscal year 2017, (c) 30% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 30% for fiscal year 2018, and (d) 40% of the stock options vest upon the attainment of an annual growth rate of Adjusted EBITDA per share of common stock of 25% for fiscal year 2019.
	A summary of stock option activity is as follows:


			Outstanding stock options

	(in thousands, except for exercise prices and term)		Number of			Range of		Weighted-				Weighted-		Aggregate
			options			exercise		average				average		intrinsic
						prices		exercise				contractual		value
								price				term
												(in years)
	Outstanding as of January 31, 2014		6,369			$1.10 - 4.50		$	1.77			6.34		$	14,621

	Granted		1,946			$14.00 - 18.93		$	14.29

	Exercised		(1,793	)		$0.50 - 2.50		$	1.34

	Forfeited		(169	)		$1.25 - 14.00		$	9.97

	Outstanding as of October 31, 2014		6,353			$0.10 - 18.93		$	4.79			7.03		$	99,157

	A summary regarding non-vested and exercisable stock options is as follows:


			Non-vested stock options							Exercisable stock options

	(in thousands, except for exercise prices and term)		Number of			Weighted-				Number of			Weighted-			Weighted-	Aggregate
			shares			average				shares			average			average	intrinsic
						grant date							exercise			contractual	value
						fair value							price			term
																(in years)
	Balance as of January 31, 2014		2,812			$	0.26			3,557			$	1.3		5.03	$	9,835

	Granted		1,946			$	5.25			—			$	—

	Vesting		(2,216	)		$	0.22			2,216			$	1.25

	Exercised		—			$	—			(1,793	)		$	1.34

	Forfeited/expired		(164	)		$	3.61			(5	)		$	2.25

	Balance as of October 31, 2014		2,378			$	4.15			3,975			$	0.8		5.59	$	77,916

	Vested and expected to vest as of October 31, 2014									4,772			$	2.01		6.17	$	87,742

	The aggregate intrinsic value in the tables above represents the difference between the estimated fair value of common stock and the exercise price of outstanding, in-the-money stock options.
	The total intrinsic value of stock options exercised in the three and nine months ended October 31, 2014 was $479,000 and $8.4 million, respectively, and $20,000 and $155,000 for the three and nine months ended October 31, 2013, respectively.
	The key input assumptions that were utilized in the valuation of the stock options granted during the three and nine months ended October 31, 2014 and 2013 are as follows:


			Three months ended October 31,						Nine months ended October 31,

			2014			2013			2014			2013

	Expected dividend yield		—	%		—	%		—	%		—	%

	Expected stock price volatility		32.9	%		31.3	%		32.9	%		31.3	%

	Risk-free interest rate		1.93	%		0.67	%		1.93% - 2.24%			0.35% - 0.67%

Expected life of options		6.25 years			3 years			6.25 years			3 years

The determination of the fair value of stock options on the date of grant using an option pricing model is affected by the Company's stock price as well as assumptions regarding a number of complex and subjective variables. Expected volatility is determined using weighted average volatility of publicly traded peer companies. The Company expects that it will begin using the weighted average volatility of peer publicly traded companies in addition to its own historical volatility, as that history grows over time. The risk-free interest rate is determined by using published zero coupon rates on treasury notes for each grant date given the expected term on the options. The dividend yield of zero is based on the fact that the Company expects to invest cash in operations. The Company uses the "simplified" method to estimate expected term as determined under Staff Accounting Bulletin No. 110 due to the lack of option exercise history as a public company.
As of October 31, 2014, the weighted-average vesting period of non-vested awards expected to vest approximates 3.5 years; the amount of compensation expense the Company expects to recognize for stock options vesting in future periods approximates $1.4 million.
During the three and nine months ended October 31, 2014, the Company recorded compensation expense of $325,000 and $793,000, respectively, of which $0 and $436,000 related to the performance-based options based on the Company's probability assessment of attaining its Adjusted EBITDA target and consummation of the IPO.

Fair_value

Fair value	9 Months Ended
	Oct. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair value	'
	Fair value
	A derivative liability was recorded related to the Company’s series D-3 redeemable convertible preferred stock due to stated features allowing for redemption equal to the greater of the fair value per share of series D-3 redeemable convertible preferred stock, or the liquidation preference per share of series D-3 redeemable convertible preferred stock. The derivative instrument is recorded at its fair value, using an option pricing model, and is adjusted to fair value as of the end of each reporting period. Changes in the fair value of derivative instruments are recognized currently in the condensed consolidated financial statements. The Company has classified this derivative financial instrument as Level 3 in the fair value hierarchy. The Company continued to record adjustments to the fair value of the derivative liability until March 31, 2014, at which time the Company modified the terms of the series D-3 redeemable convertible preferred stock. As a result of the modifications, the Company reclassified the aggregate fair value of the liability to additional paid-in capital.
	The following table includes a roll forward of the amounts for the three and nine months ended October 31, 2014 and 2013 for instruments classified within Level 3. The classification within Level 3 is based upon significance of the unobservable inputs to the overall fair value measurement.


		Three months ended October 31,					Nine months ended October 31,

	(in thousands)	2014			2013		2014			2013

	Balance at beginning of period	$	—		$	818	$	6,182		$	818

	Loss on revaluation	—			109		735			109

	Elimination of liability due to removal of FMV provision	—			—		(6,917		)	—

	Balance at end of period	$	—		$	927	$	—		$	927

	The following table summarizes the significant quantitative inputs and assumptions used for items categorized in Level 3 of the fair value hierarchy as of January 31, 2014:
	Series D-3 redeemable convertible preferred stock derivative liability


		January 31, 2014

	Market value of common stock on measurement date	$	4.06

	Projected exercise price	$	2.64

	Risk-free interest rate	0.06		%

	Expected lives	180 days

	Expected volatility	25.2		%

	Probability of liquidation event	—		%


	There are no other financial instruments that are considered Level 1 or Level 2 as of October 31, 2014 and January 31, 2014.

Related_party_transactions

Related party transactions	9 Months Ended
Related party transactions	Oct. 31, 2014
Related Party Transactions [Abstract]	'
Related party transactions	'
	Related party transactions
	The Company had entered into a consulting agreement with a company owned by the President and Chief Executive Officer of the Company. For the three and nine months ended October 31, 2014 amounts paid to this company under the terms of the consulting agreement were $0 and $162,000, respectively, and $81,000 and $369,000 for the three and nine months ended October 31, 2013, respectively. In connection with the consummation of the Company's IPO, this consulting agreement was terminated.

Summary_of_business_and_signif1

Summary of business and significant accounting policies (Policies)	9 Months Ended
	Oct. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Principles of consolidation	'
Principles of consolidation	Principles of consolidation—The condensed consolidated financial statements include the accounts of HealthEquity, Inc. and its wholly owned subsidiaries, First HSA, LLC, First Horizon MSaver, Inc., HEQ Insurance Services, Inc., and HealthEquity Advisors, LLC (collectively referred to as the "Company"). All significant intercompany balances and transactions have been eliminated.
Recent accounting pronouncements	'
Recent accounting pronouncements	Recent accounting pronouncements—On May 28, 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in GAAP when it becomes effective. The new standard is effective for our annual and interim reporting periods beginning February 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on the consolidated financial statements and related disclosures

Net_income_per_share_attributa1

Net income per share attributable to common stockholders (Tables)	9 Months Ended
	Oct. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The following table sets forth the computation of basic and diluted net income per share attributable to common stockholders:


	(in thousands, except per share data)	Three months ended October 31,						Nine months ended October 31,

		2014			2013			2014			2013

	Numerator (basic and diluted):

	Net income	$	3,049		$	1,978		$	8,795		$	5,950

	Add back (deduction): accretion of redeemable convertible preferred stock	—			(245		)	4,021			(925		)

	Less: dividend on redeemable convertible preferred stock and dividend on convertible preferred stock	(21		)	(650		)	(1,286		)	(1,951		)

	Less: undistributed income attributed to redeemable convertible preferred stockholders	(8		)	(476		)	(1,285		)	(1,357		)

	Net income attributable to common stockholders for basic earnings per share	$	3,020		$	607		$	10,245		$	1,717

	Add back: dividend of redeemable convertible preferred stock	15			241			1,286			723

	Add back (deduction): accretion on redeemable convertible preferred stock and dividend on convertible preferred stock	—			75			(4,021		)	284

	Add back: series D-3 derivative liability revaluations	—			—			735			—

	Add back: adjustment to undistributed income attributed to redeemable convertible preferred stockholders	1			290			1,285			796

	Net income attributable to common stockholders for diluted earnings per share	$	3,036		$	1,213		$	9,530		$	3,520



	Denominator (basic):

	Weighted-average common shares outstanding	53,678			5,582			23,232			5,548

	Denominator (diluted):

	Weighted-average common shares outstanding	53,678			5,582			23,232			5,548

	Effect of potential dilutive securities:

	Weighted-average dilutive effect of stock options	2,944			1,156			3,290			1,168

	Weighted-average dilutive effect of common shares from stock warrants	3			2,579			1,634			2,581

	Dilutive effect from preferred stock assuming conversion	928			19,408			21,896			19,408

	Weighted-average common shares outstanding	57,553			28,725			50,052			28,705

	Net income per share attributable to common stockholders:

	Basic	$	0.06		$	0.11		$	0.44		$	0.31

	Diluted	$	0.05		$	0.04		$	0.19		$	0.12

Property_and_equipment_Tables

Property and equipment (Tables)	9 Months Ended
	Oct. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment	'
	Property and equipment consisted of the following as of October 31, 2014 and January 31, 2014:


	(in thousands)	31-Oct-14			31-Jan-14

	Leasehold improvements	$	482		$	329

	Furniture and fixtures	1,317			1,094

	Computer equipment	4,176			3,075

	Property and equipment, gross	5,975			4,498

	Accumulated depreciation	(3,287		)	(2,506		)

	Property and equipment, net	$	2,688		$	1,992

Intangible_assets_and_goodwill1

Intangible assets and goodwill (Tables)	9 Months Ended
	Oct. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets	'
	The gross carrying amount and associated accumulated amortization of intangible assets is as follows as of October 31, 2014 and January 31, 2014:


	(in thousands)	31-Oct-14			31-Jan-14

	Amortized intangible assets:

	Capitalized software development costs	$	9,073		$	5,290

	Software	4,532			3,351

	Acquired intangible member assets	24,563			24,563

	Intangible assets, gross	38,168			33,204

	Accumulated amortization	(11,918		)	(8,513		)

	Intangible assets, net	$	26,250		$	24,691

Redeemable_convertible_preferr1

Redeemable convertible preferred stock and convertible preferred stock (Tables)	9 Months Ended
	Oct. 31, 2014
Equity [Abstract]	'
Schedule of convertible preferred stock	'
	Redeemable convertible preferred stock and convertible preferred stock as of January 31, 2014 consisted of the following:


		Shares
	Series	Authorized	Issued and	Liquidation		Carrying
			outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	22,533	$	22,232

	Series D-1	9,000	5,835	8,464		8,340

	Series D-2	3,200	440	719		709

	Series D-3	7,500	4,323	11,412		15,433

	Total redeemable convertible preferred stock	26,473	17,349	$	43,128	$	46,714

	Convertible preferred stock:
	Series A	2,000	2,000	$	3,291	$	2,000

	Series B	4,738	4,156	9,473		6,129

	Total convertible preferred stock	6,738	6,156	$	12,764	$	8,129

Schedule of redeemable convertible preferred stock	'
	Redeemable convertible preferred stock and convertible preferred stock as of January 31, 2014 consisted of the following:


		Shares
	Series	Authorized	Issued and	Liquidation		Carrying
			outstanding	preference		value
	Redeemable convertible preferred stock:
	Series C	6,773	6,751	$	22,533	$	22,232

	Series D-1	9,000	5,835	8,464		8,340

	Series D-2	3,200	440	719		709

	Series D-3	7,500	4,323	11,412		15,433

	Total redeemable convertible preferred stock	26,473	17,349	$	43,128	$	46,714

	Convertible preferred stock:
	Series A	2,000	2,000	$	3,291	$	2,000

	Series B	4,738	4,156	9,473		6,129

	Total convertible preferred stock	6,738	6,156	$	12,764	$	8,129

Stock_options_Tables

Stock options (Tables)	9 Months Ended
	Oct. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of stock options	'
	A summary of stock option activity is as follows:


		Outstanding stock options

	(in thousands, except for exercise prices and term)	Number of		Range of		Weighted-				Weighted-		Aggregate
		options		exercise		average				average		intrinsic
				prices		exercise				contractual		value
						price				term
										(in years)
	Outstanding as of January 31, 2014	6,369		$1.10 - 4.50		$	1.77			6.34		$	14,621

	Granted	1,946		$14.00 - 18.93		$	14.29

	Exercised	(1,793	)	$0.50 - 2.50		$	1.34

	Forfeited	(169	)	$1.25 - 14.00		$	9.97

	Outstanding as of October 31, 2014	6,353		$0.10 - 18.93		$	4.79			7.03		$	99,157

Summary of non-vested and exercisable stock options	'
	A summary regarding non-vested and exercisable stock options is as follows:


		Non-vested stock options						Exercisable stock options

	(in thousands, except for exercise prices and term)	Number of		Weighted-				Number of			Weighted-			Weighted-	Aggregate
		shares		average				shares			average			average	intrinsic
				grant date							exercise			contractual	value
				fair value							price			term
														(in years)
	Balance as of January 31, 2014	2,812		$	0.26			3,557			$	1.3		5.03	$	9,835

	Granted	1,946		$	5.25			—			$	—

	Vesting	(2,216	)	$	0.22			2,216			$	1.25

	Exercised	—		$	—			(1,793	)		$	1.34

	Forfeited/expired	(164	)	$	3.61			(5	)		$	2.25

	Balance as of October 31, 2014	2,378		$	4.15			3,975			$	0.8		5.59	$	77,916

	Vested and expected to vest as of October 31, 2014							4,772			$	2.01		6.17	$	87,742

Summary of Assumptions	'
	The key input assumptions that were utilized in the valuation of the stock options granted during the three and nine months ended October 31, 2014 and 2013 are as follows:


		Three months ended October 31,					Nine months ended October 31,

		2014		2013			2014			2013

	Expected dividend yield	—	%	—	%		—	%		—	%

	Expected stock price volatility	32.9	%	31.3	%		32.9	%		31.3	%

	Risk-free interest rate	1.93	%	0.67	%		1.93% - 2.24%			0.35% - 0.67%

	Expected life of options	6.25 years		3 years			6.25 years			3 years

Fair_value_Tables

Fair value (Tables)	9 Months Ended
	Oct. 31, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Roll-forward of the amounts for instruments classified with Level 3	'
	The following table includes a roll forward of the amounts for the three and nine months ended October 31, 2014 and 2013 for instruments classified within Level 3. The classification within Level 3 is based upon significance of the unobservable inputs to the overall fair value measurement.


		Three months ended October 31,					Nine months ended October 31,

	(in thousands)	2014			2013		2014			2013

	Balance at beginning of period	$	—		$	818	$	6,182		$	818

	Loss on revaluation	—			109		735			109

	Elimination of liability due to removal of FMV provision	—			—		(6,917		)	—

	Balance at end of period	$	—		$	927	$	—		$	927

Summary of the significant quantitative inputs and assumptions used for items categorized in Level 3 of the fair value hierarchy	'
	Series D-3 redeemable convertible preferred stock derivative liability


		January 31, 2014

	Market value of common stock on measurement date	$	4.06

	Projected exercise price	$	2.64

	Risk-free interest rate	0.06		%

	Expected lives	180 days

	Expected volatility	25.2		%

	Probability of liquidation event	—		%

Summary_of_business_and_signif2

Summary of business and significant accounting policies (Details) (USD $)	0 Months Ended	9 Months Ended			0 Months Ended		3 Months Ended
	Aug. 05, 2014	Oct. 31, 2014	Jul. 14, 2014	Jan. 31, 2014	Aug. 05, 2014	Jul. 14, 2014	Oct. 31, 2014	Oct. 31, 2014
					IPO	Dividend Declared	Increase in Prepaid Expenses and Additional Paid-in Capital	Decrease in Cash Provided by Operating Activities
							Error in Calculation of Tax Benefits	Error in Calculation of Tax Benefits
Class of Stock [Line Items]	'	'	'	'	'	'	'	'
Shares of common stock issued	'	'	'	'	10,465,000	'	'	'
IPO price per share	'	'	'	'	$14	'	'	'
Net proceeds from IPO	'	'	'	'	$132,600,000	'	'	'
Underwriters discount and commission	'	'	'	'	10,200,000	'	'	'
Other offering expenses payable	'	'	'	'	3,700,000	'	'	'
Common and preferred stock, shares authorized	'	'	1,000,000,000	'	'	'	'	'
Common stock, shares authorized	'	900,000,000	900,000,000	900,000,000	'	'	'	'
Preferred stock, shares authorized	'	100,000,000	100,000,000	100,000,000	'	'	'	'
Preferred Stock, par value per share	'	$0.00	$0.00	$0.00	'	'	'	'
Dividends declared	'	50,000,000	'	'	'	50,000,000	'	'
Decrease in exercise price to record an adjustment to outstanding stock options	$1	'	'	'	'	'	'	'
Preferred stock converted to common stock ( in shares)	32,486,588	'	'	'	'	'	'	'
Adjustment for error caused by using incorrect fair value for calculation Tax benefit	'	'	'	'	'	'	$1,000,000	$1,000,000

Net_income_per_share_attributa2

Net income per share attributable to common stockholders (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net income	$3,049	$1,978	$8,795	$5,950
Add back (deduction): accretion of redeemable convertible preferred stock	0	-245	4,021	-925
Less: dividend on redeemable convertible preferred stock and dividend on convertible preferred stock	-21	-650	-1,286	-1,951
Less: undistributed income attributed to redeemable convertible preferred stockholders	-8	-476	-1,285	-1,357
Net income attributable to common stockholders for basic earnings per share	3,020	607	10,245	1,717
Add back: dividend of redeemable convertible preferred stock	15	241	1,286	723
Add back (deduction): accretion on redeemable convertible preferred stock and dividend on convertible preferred stock	0	75	-4,021	284
Add back: series D-3 derivative liability revaluations	0	0	735	0
Add back: adjustment to undistributed income attributed to redeemable convertible preferred stockholders	1	290	1,285	796
Net income attributable to common stockholders for diluted earnings per share	$3,036	$1,213	$9,530	$3,520
Weighted-average common shares outstanding (in shares)	53,678	5,582	23,232	5,548
Weighted-average dilutive effect of stock options (in shares)	2,944	1,156	3,290	1,168
Weighted-average dilutive effect of common shares from stock warrants (in shares)	3	2,579	1,634	2,581
Dilutive effect from preferred stock assuming conversion (in shares)	928	19,408	21,896	19,408
Weighted-average common shares outstanding (in shares)	57,553	28,725	50,052	28,705
Basic (in dollars per share)	$0.06	$0.11	$0.44	$0.31
Diluted (in dollars per share)	$0.05	$0.04	$0.19	$0.12

Net_income_per_share_attributa3

Net income per share attributable to common stockholders (Anti-dilutive securities) (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	322	14,500	164	14,400

Property_and_equipment_Schedul

Property and equipment (Schedule of property and equipment) (Details) (USD $)	Oct. 31, 2014	Jan. 31, 2014
In Thousands, unless otherwise specified	Oct. 31, 2014	Jan. 31, 2014
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$5,975	$4,498
Accumulated depreciation	-3,287	-2,506
Property and equipment, net	2,688	1,992
Leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	482	329
Furniture and fixtures	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	1,317	1,094
Computer equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	$4,176	$3,075

Property_and_equipment_Narrati

Property and equipment (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation expense	$290	$215	$776	$562

Intangible_assets_and_goodwill2

Intangible assets and goodwill (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Capitalized software development costs	$1,400	$343	$3,800	$948
Software development costs incurred and expensed	1,200	541	3,200	1,700
Amortization expense	$1,300	$936	$3,400	$2,600

Intangible_assets_and_goodwill3

Intangible assets and goodwill (Schedule of finite-lived intangible assets) (Details) (USD $)	Oct. 31, 2014	Jan. 31, 2014
In Thousands, unless otherwise specified	Oct. 31, 2014	Jan. 31, 2014
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	$38,168	$33,204
Intangible assets, net	-11,918	-8,513
Total	26,250	24,691
Capitalized software development costs	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	9,073	5,290
Software	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	4,532	3,351
Acquired intangible member assets	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, gross	$24,563	$24,563

Commitment_and_contingencies_D

Commitment and contingencies (Details) (USD $)	3 Months Ended		9 Months Ended
Commitment and contingencies (Details) (USD $)	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Office lease, additional commitment	'	'	'	'	$1,100,000
Lease expense for office space	374,000	237,000	944,000	672,000	'
Expenses for other agreements	$67,000	$62,000	$166,000	$127,000	'

Income_taxes_Details

Income taxes (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013	Jan. 31, 2014
Income Tax Disclosure [Abstract]	'	'	'	'	'
Income tax provision	$1,100	$1,280	$5,047	$3,724	'
Effective tax rate	26.50%	39.30%	36.50%	38.50%	'
Net impact of discrete tax items on effective tax rate	12.10%	'	3.10%	'	'
Unrecognized tax benefits	229	'	229	'	256
Net unrecognized tax benefits	53	'	53	'	47
Anticipated decrease in total gross unrecognized tax benefits within 12 months	$6	'	$6	'	'

Redeemable_convertible_preferr2

Redeemable convertible preferred stock and convertible preferred stock (Details) (USD $)

Oct. 31, 2014

Jul. 14, 2014

Jan. 31, 2014

Aug. 05, 2014

Oct. 31, 2014

Jan. 31, 2014

Oct. 31, 2014

Jan. 31, 2014

Oct. 31, 2014

Jan. 31, 2014

Oct. 31, 2014

Jan. 31, 2014

Oct. 31, 2014

Jan. 31, 2014

Oct. 31, 2014

Jan. 31, 2014

Oct. 31, 2014

Jan. 31, 2014

Oct. 31, 2014

Jan. 31, 2014

In Thousands, except Share data, unless otherwise specified

Common stock

Series C Redeemable convertible preferred stock

Series D1 Redeemable convertible preferred stock

Series D2 Redeemable convertible preferred stock

Series D3 Redeemable convertible preferred stock

Redeemable convertible preferred stock

Series A Convertible preferred stock

Series B Convertible preferred stock

Convertible preferred stock

Class of Stock [Line Items]

Conversion of preferred stock to common stock

32,486,588

Conversion ratio to common stock

1.38

2.27

Redeemable convertible preferred stock:

Shares authorized

6,773,000

9,000,000

3,200,000

7,500,000

26,473,000

Shares issued

6,751,000

5,835,000

440,000

4,323,000

17,349,000

Shares outstanding

17,349,000

6,751,000

5,835,000

440,000

4,323,000

17,349,000

Liquidation preference

$22,533

$8,464

$719

$11,412

$43,128

Carrying value

46,714

22,232

8,340

709

15,433

46,714

Convertible preferred stock:

Shares authorized

100,000,000

2,000,000

4,738,000

6,738,000

Shares issued

2,000,000

4,156,000

6,156,000

Shares outstanding

2,000,000

4,156,000

6,156,000

Liquidation preference

3,291

9,473

12,764

Carrying value

$2,000

$6,129

$8,129

Common_stock_warrants_Details

Common stock warrants (Details) (USD $)

Oct. 31, 2014

Jan. 31, 2014

Nov. 30, 2005

Oct. 31, 2014

Jan. 31, 2014

Feb. 29, 2004

Jan. 31, 2014

Sep. 30, 2005

Jan. 31, 2014

Aug. 31, 2006

Jan. 31, 2014

7-May-07

Jan. 31, 2014

Aug. 31, 2008

Oct. 31, 2014

Jan. 31, 2014

Aug. 31, 2011

In Thousands, except Per Share data, unless otherwise specified

Series A Convertible Preferred Stock, Exercisable Through November 2015

Series B Convertible Preferred Stock, Exercisable Through February 2014

Series B Convertible Preferred Stock, Exercisable Through Sept 2015

Series C Redeemable Convertible Preferred Stock, Exercisable Through August 2016

Series C Redeemable Convertible Preferred Stock, Exercisable Through May 7, 2015

Series D1 Redeemable Convertible Preferred Stock, Exercisable Through 2016

Series D3 Redeemable Convertible Preferred Stock, Exercisable Through August 2021

Class of Warrant or Right [Line Items]

Number of securities called by warrants

150

400

200

600

1,000

400

966

Exercise price of warrants (usd per share)

$0.80

$1.50

$0.01

Warrants exercised

340

767

Warrants forfeited

Warrants outstanding

124

350

195

590

1,000

400

199

Value of common stock warrants

$2,334

$51

$44

$66

$339

$1,600

$1,700

Stock_options_Details

Stock options (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2014	Jan. 31, 2014
Number of options	'	'
Opening balance	6,369	'
Granted	1,946	'
Exercised	-1,793	'
Forfeited	-169	'
Ending balance	6,353	6,369
Range of exercise prices (usd per share)	'	'
Beginning balance, minimum	$1.10	'
Beginning balance, maximum	$4.50	'
Granted, minimum	$14	'
Granted, maximum	$18.93	'
Exercised, minimum	$0.50	'
Exercised, maximum	$2.50	'
Forfeited, minimum	$1.25	'
Forfeited, maximum	$14	'
Ending balance, minimum	$1.10	$1.10
Ending balance, maximum	$18.93	$4.50
Weighted- average exercise price (usd per share)	'	'
Opening balance	$1.77	'
Granted	$14.29	'
Exercised	$1.34	'
Forfeited	$9.97	'
Ending balance	$4.79	$1.77
Weighted- average contractual term (in years)	'7 years 0 months 10 days	'6 years 4 months 2 days
Aggregate intrinsic value	$99,157	$14,621

Stock_options_Nonvested_and_Ex

Stock options (Non-vested and Exercisable stock options) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2014	Jan. 31, 2014
Non-vested stock options, Number of shares	'	'
Beginning balance	2,812	'
Granted	1,946	'
Vesting	-2,216	'
Forfeited/expired	-164	'
Ending balance	2,378	2,812
Non-vested stock options, Weighted average grant date fair value (usd per share)	'	'
Beginning balance	$0.26	'
Granted	$5.25	'
Vested	$0.22	'
Forfeited/expired	$3.61	'
Ending balance	$4.15	$0.26
Exercisable stock options	'	'
Number of shares, Beginning balance	3,557	'
Number of shares, Vesting	2,216	'
Number of shares, Exercised	-1,793	'
Number of shares, Forfeited/expired	-5	'
Number of shares, Ending balance	3,975	3,557
Weighted average exercise price, Beginning balance (usd per share)	$1.30	'
Weighted average exercise price, Vesting (usd per share)	$1.25	'
Weighted average exercise price, Exercised (usd per share)	$1.34	'
Weighted average exercise price, Forfeited/expired (usd per share)	$2.25	'
Weighted average exercise price, Ending balance (usd per share)	$0.80	$1.30
Weighted average contractual term (in years)	'5 years 6 months 32 days	'5 years 0 months 11 days
Aggregate intrinsic value	$77,916	$9,835
Vested and expected to vest	'	'
Number of shares	4,772	'
Weighted- average exercise price (usd per share)	$2.01	'
Weighted- average contractual term (in years)	'6 years 1 month 30 days	'
Aggregate intrinsic value	$87,742	'

Stock_options_Assumptions_Deta

Stock options (Assumptions) (Details)	3 Months Ended		9 Months Ended
Stock options (Assumptions) (Details)	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Expected stock price volatility	32.90%	31.30%	32.90%	31.30%
Risk-free interest rate	1.93%	0.67%	'	'
Expected life of options	'6 years 3 months	'3 years	'6 years 3 months	'3 years
Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rate	'	'	1.93%	0.35%
Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rate	'	'	2.24%	0.67%

Stock_options_Narrative_Detail

Stock options (Narrative) (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
Stock options (Narrative) (Details) (USD $)	Jul. 31, 2014	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013	Jan. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Number of shares authorized	'	2,600,000	'	2,600,000	'	600,000
Additional shares available for grants as percentage of capital stock outstanding	'	3.00%	'	3.00%	'	'
Increase in authorized shares	2,000,000	'	'	'	'	'
Shares available for grant	'	631,000	'	631,000	'	'
Grants to certain directors and key employees	'	'	'	1,946,000	'	'
Expiration period after termination	'	'	'	'10 years	'	'
Expiration period from termination of employment	'	'	'	'90 days	'	'
Aggregate intrinsic value	'	$479,000	$8,400,000	$20,000	$155,000	'
Weighted-average vesting period of non-vested awards expected to vest	'	'	'	'3 years 6 months	'	'
Unrecognized stock compensation expense to be recognized in future	'	1,400,000	'	1,400,000	'	'
Share based compensation	'	325,000	'	793,000	'	'
Vesting criteria for FY 2015	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Percentage of options vested	'	'	'	10.00%	'	'
Minimum adjusted EBITDA to be attained for shares to vest	'	'	'	34,500,000	'	'
Vesting criteria for FY 2016	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Percentage of options vested	'	'	'	20.00%	'	'
Annual growth rate of adjusted EBITDA per share of common stock to be achieved for options to vest	'	'	'	30.00%	'	'
Vesting criteria for FY 2017	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Percentage of options vested	'	'	'	30.00%	'	'
Annual growth rate of adjusted EBITDA per share of common stock to be achieved for options to vest	'	'	'	30.00%	'	'
Vesting criteria for FY 2018	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Percentage of options vested	'	'	'	40.00%	'	'
Annual growth rate of adjusted EBITDA per share of common stock to be achieved for options to vest	'	'	'	25.00%	'	'
Performance Shares	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Performance stock granted	'	58,000	'	1,400,000	'	'
Share based compensation	'	$0	'	$436,000	'	'
Directors and Key Employees	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Grants to certain directors and key employees	'	56,000	'	487,500	'	'
Vesting period	'	'4 years	'	'	'	'
Directors and Key Employees \| Vesting Period of Four Year	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Grants to certain directors and key employees	'	'	'	405,000	'	'
Directors and Key Employees \| Vest on January 31, 2015	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Grants to certain directors and key employees	'	82,500	'	'	'	'

Fair_value_Details

Fair value (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'
Balance at beginning of period	$0	$818	$6,182	$818
Loss on revaluation	0	109	735	109
Elimination of liability due to removal of FMV provision	0	0	-6,917	0
Balance at the end of period	$0	$927	$0	$927

Fair_value_Fair_Value_Assumpti

Fair value ( Fair Value Assumptions) (Details) (Series D-3 redeemable convertible preferred stock derivative liability, Level 3, USD $)	12 Months Ended
	Jan. 31, 2013	Jan. 31, 2014
Series D-3 redeemable convertible preferred stock derivative liability \| Level 3	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Market value of common stock on measurement date (per share)	'	$4.06
Projected exercise price ( usd per share)	'	$2.64
Risk-free interest rate	0.06%	'
Expected lives	'180 days	'
Expected volatility	25.20%	'
Probability of liquidation event	0.00%	'

Related_party_transactions_Det

Related party transactions (Details) (Company owned by President and Chief Executive Officer, USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2014	Oct. 31, 2013	Oct. 31, 2014	Oct. 31, 2013
Company owned by President and Chief Executive Officer	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Amounts paid under consulting agreement	$0	$81	$162	$369